BI | pharmaphorum

News

Boehringer buys immunotherapy biotech AMAL Therapeutics

Germany’s Boehringer Ingelheim has bought the Swiss biotech AMAL Therapeutics, a privately-held Swiss biotech focused on immunotherapy and vaccines in oncology.

News

Boehringer and Sarah Cannon team for immune-oncology venture

Partnership will seek to develop two immune checkpoint inhibitor candidates.

Oncology

Interview at ASCO 26 with David Spetzler

ASCO26: AI supercharging gene-based cancer detection, with D...

Pharmaphorum caught up with Caris Life Science's David Spetzler to talk about how agentic AI is empowering whole genome sequencing in cancer detection

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

BI

Editor's Picks